Drug
Flumatinib
Flumatinib: highest development phase Post-Market, developed by Hansoh Pharmaceutical, Jiangsu Hengrui Medicine. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Hansoh Pharmaceutical, Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Flumatinib NCT05367765 | Post-Market | CML, Chronic Phase |
| flumatinib NCT01503502 | Phase 2 | Myelogenous Leukemia, Chronic |
Latest
No recent events.
Follow Flumatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.